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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) Gag polyprotein is necessary and sufficient to
assemble non-infectious particles. Given that HIV-1 subverts many host proteins at all stages of its life cycle, it is
essential to identify these interactions as potential targets for antiretroviral therapy.
Findings: This work demonstrates the use of proximity-dependent biotin identification (BioID) of host proteins and
complexes that are proximal to the N-terminal domains of the HIV-1 Gag polyprotein. Two of the hits identified in
the BioID screen were validated by immunoprecipation and confirmed the interaction of DDX17 and RPS6 with
HIV-1 Gag.
Conclusions: Our results show that BioID is both a successful and complementary method to screen for nearby
interacting proteins of HIV-1 Gag during the replicative cycle in different cell lines.
Findings
Human immunodeficiency virus type 1 (HIV-1) is the
etiological agent of acquired immunodeficiency syndrome
(AIDS), which specifically infects CD4+ T-cells, macro-
phages and dendritic cells. The integrated proviral DNA is
transcribed to generate multiply and singly spliced and
full-length (vRNA) messenger RNAs (mRNA). vRNA acts
as both the mRNA for the Gag and Gag-Pol polyprotein
precursors, and the genome that is encapsidated into as-
sembling particles [1]. The structural polyprotein Gag
mediates virus assembly by trafficking to the plasma mem-
brane, where it multimerizes to form spherical immature
virus particles that are then released [2]. During the
budding process, the Gag precursor is cleaved by HIV-1
protease into mature Gag proteins p17 matrix (MA), p24
capsid (CA), p7 nucleocapsid (NC) and p6. The small size
of the HIV-1 genome makes it reliant on host cellular ma-
chineries to replicate and interacts with host factors in
order to neutralize host defenses and elicit pathogenesis.
Expression of BirA*-Gag
The structural protein Gag is sufficient by itself to pro-
duce HIV-1 virus-like particles (VLPs). VLPs cannot
undergo a full replication cycle nor produce new pro-
geny virus, which has allowed them to be applied to
gene therapy, as they can enter target cells to deliver
specific genes [3]. The goal of this study was to investi-
gate potential novel host proteins that interact with the
HIV-1 Gag polyprotein using a proximity-dependent
biotin identification (BioID) screen [4]. This approach
relied on the proximity-dependent biotinylation of
nearby and interacting proteins by a promiscuous bio-
tin ligase, BirA*, that was fused to the N-terminus of
HIV-1 Gag. The biotinylated proteins were then affinity
purified and identified by LC-tandem mass spectrom-
etry (MS). To this end, we cloned HIV-1 Gag into
pcDNA3.1 mycBioID (Addgene plasmid 35700) [4] to
generate BirA*-Gag (Fig. 1a). Jurkat (T lymphocyte)
and HeLa cells were transiently transfected with BirA*
or BirA*-Gag and protein expression levels were deter-
mined by Western blot analysis (Fig. 1b). As shown in
Fig. 1b, as a result of a lower transfection efficiency, Jurkat
cells expressed the BirA*-Gag at a much lower level than
did the HeLa cells. Immunofluorescence demonstrated
that there was extensive colocalization of the MYC and
p24 fluorescence in BirA*-Gag-expressing cells (Fig. 1c,
middle panels). The BirA*-Gag fusion protein was localized
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appropriately in the cytoplasm and to the plasma mem-
brane (Fig. 1c, bottom panels), as compared to cells trans-
fected with the HIV-1-expressing plasmid pNL4-3 (Fig. 1c,
bottom panels).
Identification of potential cellular interacting partners of
BirA*-Gag
To identify proximal interactors for HIV-1 Gag, we trans-
fected Jurkat cells with BirA*-Gag or BirA* alone in
medium supplemented with 50 μM Biotin (Sigma). Precipi-
tation and LC-tandem MS identification of biotinylated
proteins revealed 64 unique peptide hits that represent 47
proteins (Fig. 2a and Additional file 1: Table S1). Data were
subjected to ontology analysis using PANTHER (http://
www.pantherdb.org/) [5, 6]. In biological process, the most
clusters identified were: metabolic process, cellular process
and cellular component organization or biogenesis; whereas
binding, catalytic activity and structural molecule activity
dominated the clusters in molecular function (Fig. 2b). The
protein classes related to nucleic acid binding were the
most enriched with transferase, transfer/carrier protein and
extracellular matrix protein exclusively found in BirA*-Gag
(Fig. 2b). Physical and genetic interactions, pathways, and
protein domain similarity between the genes linked with
BirA*-Gag were mapped using GeneMANIA (http://
www.genemania.org) [7] (Fig. 2c). Compared to the
Fig. 1 Expression and localization of recombinant HIV-1 Gag. a Diagram of the expression cassette encoding MYC tagged BirA* alone and MYC-BirA* fused
to the N-terminus of HIV-1. b Jurkat or HeLa cells were transfected with BirA* or BirA*-Gag for 24 h. The expression levels of BirA* and BirA*-Gag were
evaluated by Western blot using anti-MYC (US Biological Life Sciences, M9601-30), anti-p24 (NIH, 183-H12-5C) and anti-actin (Abcam, ab8226) antibodies.
c Immunofluorescence of Jurkat (left panels) or HeLa (right panels) cells transfected with BirA*, BirA*-Gag or the HIV-1-expressing plasmid (pNL4-3).
Paraformaldehyde-fixed cells were incubated with primary anti-MYC and anti-p24 antibodies for 1 h at 37 °C and secondary antibodies Alexa Fluor 488
anti-mouse IgG and Alexa Fluor 594 anti-rabbit IgG (Molecular Probes). Coverslips were mounted in ProLong Gold antifade reagent (Molecular Probes) with
DAPI to stain the nuclei. Images were acquired using a Wave FX Spinning disc confocal microscope with a 63x objective. Scale bar indicates 10 μm
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distribution of GO terms across the whole human prote-
ome, the largest set of significantly enriched (p-value
3.16E-06) in both BirA* and BirA*-Gag groups were
mRNA-binding proteins that participate in ribosomal
structure. This may reflect that many RNA-binding pro-
teins were physically close to BirA*during its translation.
However, a number of these factors were exclusive to the
BirA*-Gag hits, including the ribosomal protein (RP) S2,
S3, S5, S6, L11, S16, L27, L28, L29 and L35, which have
previously been shown to interact with different HIV-1
proteins (Additional file 1: Table S1). HIV-1 MA domain
of Gag has been previously shown to interact with pro-
teins involved in translation such as the putative histidyl-
tRNA synthetase HO3, and the GTPase eIF5B [8, 9].
eIF5B, identified in Additional file 1: Table S1, has also
been previously shown to interact with HIV-1 Gag [9, 10]
and this association has the potential to regulate transla-
tion [9]. Moreover, picornaviruses have been shown to in-
hibit host cell translation early in infection in part by
cleavage of eIF5B [11].
The host’s first line of defense against viral infection
is the innate immune system whose activation leads to
the production of proinflammatory cytokines and type I
interferon (IFN) responses. The only protein classified
within the GO immune system process was the IFN-
inducible protein 16 (IFI16). Several classes of nucleic
acid sensors have been implicated in HIV-1 RNA and
DNA recognition [12] and IFI16 has been shown to co-
localize and associated with lentiviral DNA in the cyto-
plasm of macrophages [13]. Additionally, HIV-1 disease
progression was affected by the genetic variation in
IFI16 with a particular single-nucleotide polymorphism
in its promoter region being associated with higher
CD4+ T cell counts [14]. A potential interaction be-
tween IFI16 and Gag may suggest a HIV-1 counter-
measure to this important host defense.
Identified in Additional file 1: Table S1, Lyric (also
known as Metadherin or astrocyte-elevated gene 1
(AEG-1)) was first identified as a HIV-1 inducible gene
and has been suggested to play a role in a positive-
Fig. 2 Identification of potential Gag proximal and interacting partners. Jurkat cells were transfected with BirA* or BirA*-Gag in medium supplemented
with 50 μM Biotin (Sigma). Cell lysates were harvested 24 h post-transfection. Dynabeads MyOne Streptavidin C1 (Life Technologies) were used to
precipitate biotinylated proteins from 1 mg of lysate as described by the manufacturer. The eluted proteins were separated on 4-15 % SDS-PAGE
(Bio-Rad), the bands excised and analyzed by LC-tandem MS at SAMS Centre for proteomics, University of Calgary. a Venn diagram depicting
the number of overlapping hits between Gag-interacting proteins. b Genes families and subfamilies were grouped and classified, using PANTHER,
according to their function in three different ways: biological process, molecular function and protein class. c GeneMANIA (used in automatically
selected weighting method) was used to determine known interactions between input genes and how they interact. The relationships between genes
in the network included physical and genetic interactions, pathways and protein domain similarity
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feedback loop promoting HIV-1 replication [15] and
has also been implicated in HIV-associated neuropathy
[16, 15]. Engeland and colleagues recently demon-
strated that Lyric interacts specifically with Gag and is
incorporated into HIV-1 virions, where it is cleaved by
the viral protease [17].
Validation of BirA*-Gag interactions
Selected cellular targets identified by LC-tandem MS
(DEAD-box RNA helicase 17 (DDX17) and RPS6) as po-
tential interactors of BirA*-Gag were then investigated to
validate the results of the screen. Co-immunoprecipitations
were performed using antisera against GFP and Flag follow-
ing transfection of HeLa cells with GFP or Gag-GFP
[18] and Flag or Flag-Gag, respectively. Endogenous
DDX17 and RPS6 were readily detected in the eluate
from Gag-GFP—and Flag-Gag-expressing cells but
was completely absent in the eluate from GFP—or
Flag-expressing cells (Fig. 3). Similar results were ob-
tained following a MYC immunoprecipitation using
the BirA* and BirA*-Gag constructs shown in Fig. 1a
(data not shown). DDX17 can form heterodimers with
its paralog DDX5 [19] and has been shown to be im-
portant for the production of HIV-1 particles and
HIV-1 RNA nuclear export [20, 21]. As a downstream
substrate of the translational activator S6K1, RPS6 is
one of the key components of the protein synthesis
machinery and was shown to associate with Staufen1
ribonucleoprotein complexes isolated from HIV-1-
expressing cells [22]. RPS6 is a key component of the
host protein synthesis machinery and is important in
modulating the overall translational capacity of cells.
Different antiretroviral drugs have been shown to
decrease phosphorylation of RPS6 in myocytes and
negatively affect protein synthesis in these cells [23].
Recently, Ritchie and colleagues published a study in
which they examined the interactions of Gag versus a
MA-deleted Gag mutant in virus-producing HEK 293 T
cells using BioID [24]. Fifty cellular proteins were biotinyl-
ated by wild-type Gag, however, only one, Lyric over-
lapped with our list (Additional file 1: Table S1). The
BioID approach is very useful for identifying weak and/or
transient interactions (because biotinylation occurs before
solubilization) and is amenable to temporal regulation.
However, limitations include the neighbouring proteins
having available primary amines to be biotinylated and
consequently, the absence of biotinylation does rule out
interaction or proximity [4]. Our study taken together
with the one performed by Ritchie and colleagues high-
light the importance of the chosen location of the BirA*
tag in the design of a construct, as their construct encoded
BirA* within Gag between the MA and CA domains [24].
The practical labeling radius of BirA* may be as small as
10 nm [25] and therefore insertion of BirA* adjacent to or
within various Gag domains will affect the pool of bio-
tinylated interacting proteins. Another limitation may be
the choice of control pulldown, expressing BirA* alone
may have inadvertently eliminated, in addition to non-
specific interactors, some specific Gag interactors that also
interact with BirA*. This short report thoroughly validated
Fig. 3 Validation of BirA*-Gag interactions by immunoprecipitation and Western blot. The Gag coding sequence was cloned into the pCI-Neo-Flag
(Flag) (Life Technologies) between XhoI and NotI to express Flag-Gag. HeLa cells were transfected with either GFP or Gag-GFP (left panels) or Flag or
Flag-Gag (right panel) for 24 h. Cell lysates were washed with PBS and collected using NP40 lysis buffer (50 mM Tris pH 7.8; 150 mM NaCl; 0.5 mM
EDTA; 0.5 % Nonidet P-40) supplemented with Complete protease inhibitor (Roche). Cell lysates were quantified by the Bradford assay (Bio-Rad) and
1 mg of protein was immunoprecipitated with anti-MYC tag mAb-Magnetic beads for 2 h as described by the manufacturer (MLB). The bound
complexes were analyzed by SDS-PAGE using anti-p24 (NIH, 183-H12-5C), anti-DDX17 (Abcam, ab24601) and anti-S6 Ribosomal Protein (Cell Signalling
54D2) antibodies
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BioID as a rapid and reliable method of screening for both
proximal and interacting proteins.
Additional file
Additional file 1: Proteins exclusively biotinylated by BirA*-Gag
with known HIV-1 interactions. (PDF 96 kb)
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